NCT06475586CompletedPhase 4
Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 1 Jul 2024
Brief summary (registry, in English)
The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 11 Jun 2024
- Start date
- 3 May 2023
- Primary completion date
- 1 Mar 2024
- Lead sponsor
- University of Banja Luka
- Diseases
- Psoriasis, Type 2 diabetes
- NCT number
- NCT06475586
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 30
- From 3 May 2023 to the primary completion date, 1 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Drugs that can cause the appearance of psoriasis (lithium, systemic antimalarials, systemic corticosteroids) - for the past 3 months,
- Systemic therapy of vulgaris psoriasis 3 months before inclusion in the study,
- Patients on therapy with other GLP-1 RAs except semaglutide (liraglutide, dulaglutide, lixisenatide), SGLT-2 inhibitors (empagliflozin and dapagliflozin) and NSAIDs, photo UVB therapy,
Other illness
- Other chronic, inflammatory diseases (data obtained by reviewing the medical history),
Other
- Other forms of psoriasis,
- Patients who did not personally sign consent to participate in the study.
Who the study is looking for
- Patients who signed a personal consent to participate in the study,
- Patients with a typical clinical picture of moderately-severe to severe plaque psoriasis (PASI SCORE ≥10) and
- DMT2 diagnosed at least 6 months before inclusion in the study,
- Patients who were not treated with immunosuppressive therapy.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Banja Luka, Faculty of Medicine Coordinator of this site? Confirm its status | Banja Luka | Bosnia and Herzegovina | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.